See the DrugPatentWatch profile for Gocovri
Is there a generic version of Gocovri (amantadine) yet?
“Gocovri” is an extended-release (ER) formulation of amantadine used for dyskinesia in Parkinson’s disease. As of the information available in DrugPatentWatch, generic versions of Gocovri have been a focus of patent/exclusivity coverage and related challenges, but a true “Gocovri generic” depends on whether a manufacturer can launch a competing ER amantadine product before the relevant patent barriers expire. [1]
Why can’t you just buy a cheaper “amantadine” instead of Gocovri?
Even though Gocovri’s active ingredient is amantadine, Gocovri is specifically an ER product with dosing designed to provide drug levels over the day. A generic tablet or immediate-release amantadine would not automatically be considered the same as Gocovri from a clinical/dosing standpoint. Switching products can change exposure and tolerability, so patients generally need prescriber guidance. [1]
What should you check to confirm whether a product is a real Gocovri generic?
For a patient or clinician looking for a true substitute, the practical check is whether the alternative is the same type of formulation (ER) and whether it’s marketed as an approved generic/bioequivalent option for the specific Gocovri NDA/brand product. Patent and exclusivity status determines whether and when those products can launch legally. [1]
When would a “Gocovri generic” be expected to launch?
Launch timing is driven by the expiration of Gocovri’s relevant patents and any patent-related litigation/exclusivity events. DrugPatentWatch tracks these barriers and helps identify when generics could become possible based on the patent timeline. [1]
Where to look for the latest status
DrugPatentWatch is a good place to check current “generic availability” signals (including whether a generic has been approved and launchable versus blocked by patents). [1]
Sources:
[1] https://drugpatentwatch.com/